AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18854549 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-weekly oxaliplatin 85 mg/m(2) + continuous intravenous infusion (CIV) of 5‐FU without LV or two‐weekly bolus and CIV 5‐FU + LV (LV5FU2)
Number of subjects: 725
Study 18854549 — intervention group
Group type: COMPARATOR
Intervention: 5‐FU CIV or LV5FU2 alone
Number of subjects: 725
Study 17407646 — intervention group
Group type: EXPERIMENTAL
Intervention: Analogue basal-bolus insulin (insulin detemir plus insulin aspart)
Number of subjects: 0
Study 17407646 — intervention group
Group type: COMPARATOR
Intervention: Human basal-bolus insulin (Neutral Protamine Hagedorn plus human soluble insulin)
Number of subjects: 0
Study 15570501 — intervention group
Group type: COMPARATOR
Intervention: Low frequency repetitive transcranial magnetic stimulation (rTMS) at 110% motor threshold, 1 Hz, 2000 stimuli/day over 5 days
Number of subjects: 0
Study 15570501 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11136280 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg for 2 weeks (Group A)
Number of subjects: 140
Study 11136280 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg for 2 weeks (Group B)
Number of subjects: 140
Study 11136280 — intervention group
Group type: COMPARATOR
Intervention: OAC for 1 week (Group C)
Number of subjects: 140
Study 9688487 — intervention group
Group type: EXPERIMENTAL
Intervention: LLETZ under local paracervical anesthesia (Group B)
Number of subjects: 119
Study 9688487 — intervention group
Group type: COMPARATOR
Intervention: Multiple cervical punch biopsies (Group A)
Number of subjects: 119
Study 8047827 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole, 40 mg once daily
Number of subjects: 0
Study 8047827 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine, 150 mg twice daily
Number of subjects: 0
Study 8047827 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2783352 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-chain triglyceride formula
Number of subjects: 12
Study 2783352 — intervention group
Group type: COMPARATOR
Intervention: Long-chain triglyceride formula
Number of subjects: 12
Study 192405 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine oestrogens
Number of subjects: 21
Study 30770244 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine/Ketorolac combination (1.5 mg/kg lidocaine and 30 mg ketorolac)
Number of subjects: 150
Study 30770244 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine (1.5 mg/kg)
Number of subjects: 150
Study 30770244 — intervention group
Group type: COMPARATOR
Intervention: Ketorolac (30 mg)
Number of subjects: 150
Study 30511473 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine extended-release formulation (test group)
Number of subjects: 0
Study 30511473 — intervention group
Group type: COMPARATOR
Intervention: Existing strengths of lamotrigine (reference group)
Number of subjects: 0
Study 28040315 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic control assessed with the latest annual glycosylated haemoglobin (HbA1c)
Number of subjects: 129
Study 28040315 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular comorbidity
Number of subjects: 129
Study 28040315 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors
Number of subjects: 129
Study 28040315 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 129
Study 28040315 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary lifestyle
Number of subjects: 129
Study 28040315 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to Mediterranean diet
Number of subjects: 129
Study 25577145 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilated group (VG)
Number of subjects: 30
Study 25577145 — intervention group
Group type: COMPARATOR
Intervention: Non-ventilated group (NVG)
Number of subjects: 30
Study 23529719 — intervention group
Group type: EXPERIMENTAL
Intervention: Patellar resurfacing
Number of subjects: 1725
Study 23529719 — intervention group
Group type: COMPARATOR
Intervention: Nonresurfacing
Number of subjects: 1725
Study 21142756 — intervention group
Group type: EXPERIMENTAL
Intervention: Analogical transfer approach (experimental group)
Number of subjects: 94
Study 21142756 — intervention group
Group type: COMPARATOR
Intervention: Conventional approach (control group)
Number of subjects: 94
Study 21142756 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 94
Study 19514188 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture at Qiuxu (GB 40)
Number of subjects: 275
Study 19514188 — intervention group
Group type: COMPARATOR
Intervention: Electroacupuncture at Tianshu (ST 25)
Number of subjects: 275
Study 19514188 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up survey after 3 months
Number of subjects: 275
Study 19514188 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up survey after 6 months
Number of subjects: 275
Study 17467513 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (40-160 mg per day)
Number of subjects: 3081
Study 17467513 — intervention group
Group type: COMPARATOR
Intervention: Control (other treatment without angiotensin receptor blockers)
Number of subjects: 3081
Study 15011856 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon plasma coagulation (ARCO 2000 ES unit, group A)
Number of subjects: 100
Study 15011856 — intervention group
Group type: COMPARATOR
Intervention: Injection sclerotherapy (diluted adrenalin 1:10,000 plus polidocanol 1%, group B)
Number of subjects: 100
Study 15011856 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 100
Study 11724223 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol/APAP (75 mg/650 mg)
Number of subjects: 1197
Study 11724223 — intervention group
Group type: COMPARATOR
Intervention: Tramadol (75 mg)
Number of subjects: 1197
Study 11724223 — intervention group
Group type: COMPARATOR
Intervention: APAP (650 mg)
Number of subjects: 1197
Study 11724223 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen (400 mg)
Number of subjects: 1197
Study 11724223 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1197
Study 8990057 — intervention group
Group type: EXPERIMENTAL
Intervention: L-dopa
Number of subjects: 10
Study 8990057 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 8484506 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal meperidine (6 sprays, 27 mg)
Number of subjects: 60
Study 8484506 — intervention group
Group type: COMPARATOR
Intervention: Intravenous meperidine (6 mL, 27 mg)
Number of subjects: 60
Study 8484506 — intervention group
Group type: COMPARATOR
Intervention: Intranasal NaCl 0.9% (6 sprays)
Number of subjects: 60
Study 8484506 — intervention group
Group type: COMPARATOR
Intervention: Intravenous NaCl 0.9% (6 mL)
Number of subjects: 60
Study 2892582 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevantolol (200 mg) + Hydrochlorothiazide (25 mg)
Number of subjects: 22
Study 2892582 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (80 mg)
Number of subjects: 22
Study 29534407 — intervention group
Group type: EXPERIMENTAL
Intervention: 0-50% preset ASIR-V (an interval of 10%) applied in groups A-F, with group E showing 40% preset ASIR-V as optimal.
Number of subjects: 180
Study 29534407 — intervention group
Group type: EXPERIMENTAL
Intervention: Group E (40% preset ASIR-V)
Number of subjects: 180
Study 29534407 — intervention group
Group type: COMPARATOR
Intervention: Groups B-F (with varying preset ASIR-V)
Number of subjects: 180
Study 29534407 — intervention group
Group type: EXPERIMENTAL
Intervention: Groups A-F
Number of subjects: 180
Study 26404844 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal Oxytocin (OT) administration (40 IU)
Number of subjects: 77
Study 26404844 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 24394704 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavanol-rich soluble cocoa product (7.5 g per serving, 2 servings per day, providing 45.3 mg flavanols per day)
Number of subjects: 44
Study 24394704 — intervention group
Group type: COMPARATOR
Intervention: Milk (control group)
Number of subjects: 44
Study 22426371 — intervention group
Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted trivalent influenza subunit vaccine Fluad (®)
Number of subjects: 357
Study 22426371 — intervention group
Group type: EXPERIMENTAL
Intervention: Doubling H3N2 antigen content
Number of subjects: 357
Study 22426371 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher doses of MF59 (®)
Number of subjects: 357
Study 21040545 — intervention group
Group type: EXPERIMENTAL
Intervention: Directly-observed therapy (DOT)
Number of subjects: 216
Study 21040545 — intervention group
Group type: COMPARATOR
Intervention: Self-administered therapy (SAT)
Number of subjects: 216
Study 18536785 — intervention group
Group type: EXPERIMENTAL
Intervention: Sipuleucel-T (APC-8015)
Number of subjects: 0
Study 18536785 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 16640103 — intervention group
Group type: EXPERIMENTAL
Intervention: Indinavir (IDV) 800 mg three times daily with zidovudine (AZT)/lamivudine (3TC) twice daily
Number of subjects: 103
Study 16640103 — intervention group
Group type: COMPARATOR
Intervention: Indinavir/ritonavir (IDV/RTV) 800/100 mg twice daily with zidovudine (AZT)/lamivudine (3TC) twice daily
Number of subjects: 103
Study 12894981 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiparameter approach using Nakagami and K distributions for classification of breast masses
Number of subjects: 99
Study 12894981 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of the discriminant with the level of suspicion values of the radiologist
Number of subjects: 99
Study 10905437 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulation
Number of subjects: 40
Study 10905437 — intervention group
Group type: COMPARATOR
Intervention: Chemonucleolysis
Number of subjects: 40
Study 10905437 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 8796408 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of muscle relaxant
Number of subjects: 53
Study 8796408 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous skeletal muscle paralysis for longer than 24 h
Number of subjects: 53
Study 8796408 — intervention group
Group type: COMPARATOR
Intervention: No paralysis
Number of subjects: 53
Study 8796408 — intervention group
Group type: EXPERIMENTAL
Intervention: Paralysed patients
Number of subjects: 53
Study 1636580 — intervention group
Group type: COMPARATOR
Intervention: Standard dose (1200 mg/day for 14 days)
Number of subjects: 92
Study 1636580 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose (2400 mg/day for 7 days)
Number of subjects: 92
Study 4032694 — intervention group
Group type: EXPERIMENTAL
Intervention: Ordinary dose fentanyl (15 mcg/kg)
Number of subjects: 26
Study 4032694 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate dose fentanyl (37 mcg/kg)
Number of subjects: 26
Study 31123801 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecdysterone supplementation
Number of subjects: 46
Study 30408115 — intervention group
Group type: EXPERIMENTAL
Intervention: CAB LA 600 mg IM every 8 weeks
Number of subjects: 199
Study 30408115 — intervention group
Group type: EXPERIMENTAL
Intervention: CAB LA 800 mg IM every 12 weeks
Number of subjects: 199
Study 30408115 — intervention group
Group type: EXPERIMENTAL
Intervention: CAB LA (both doses)
Number of subjects: 199
Study 30408115 — intervention group
Group type: EXPERIMENTAL
Intervention: CAB LA
Number of subjects: 199
Study 30408115 — intervention group
Group type: COMPARATOR
Intervention: PBO (placebo)
Number of subjects: 199
Study 26537369 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline hydrochloride ointment (MHO)
Number of subjects: 40
Study 26537369 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin eye ointment (EEO)
Number of subjects: 40
Study 26537369 — intervention group
Group type: COMPARATOR
Intervention: Control group (no topical antibiotics)
Number of subjects: 40
Study 25163993 — intervention group
Group type: EXPERIMENTAL
Intervention: practical training of body contact
Number of subjects: 20
Study 25163993 — intervention group
Group type: COMPARATOR
Intervention: parent counseling on body contact
Number of subjects: 20
Study 22333852 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical prostaglandin analogues (PGAs) administered over 24 weeks
Number of subjects: 75
Study 20833738 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) at a target dose of 2 g/day
Number of subjects: 105
Study 20833738 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine (AZA) at a target dose of 2 mg/kg/day
Number of subjects: 105
Study 20833738 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 105
Study 20833738 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine (AZA)
Number of subjects: 105
Study 20833738 — intervention group
Group type: EXPERIMENTAL
Intervention: Both MMF and AZA
Number of subjects: 105
Study 17466479 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-field MRI (0.2 T)
Number of subjects: 27
Study 17466479 — intervention group
Group type: COMPARATOR
Intervention: High-field MRI (1.5 T)
Number of subjects: 27
Study 16338269 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium-channel blockers
Number of subjects: 15904
Study 16338269 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretics
Number of subjects: 15904
Study 16338269 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 15904
Study 16338269 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors
Number of subjects: 15904
Study 16338269 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple antihypertensive agents
Number of subjects: 15904
Study 16338269 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality
Number of subjects: 15904
Study 11889016 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cyclophosphamide pulse therapy
Number of subjects: 26
Study 11889016 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide
Number of subjects: 26
Study 10567782 — intervention group
Group type: EXPERIMENTAL
Intervention: gemifloxacin 10 min before Maalox
Number of subjects: 16
Study 10567782 — intervention group
Group type: EXPERIMENTAL
Intervention: gemifloxacin 3 h after Maalox
Number of subjects: 16
Study 10567782 — intervention group
Group type: EXPERIMENTAL
Intervention: gemifloxacin 2 h before Maalox
Number of subjects: 16
Study 10567782 — intervention group
Group type: EXPERIMENTAL
Intervention: gemifloxacin administration
Number of subjects: 16
Study 7595910 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilvadipine
Number of subjects: 25
Study 7595910 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 25
Study 1697822 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide with doxorubicin (Group 1: n = 17)
Number of subjects: 39
Study 1697822 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide with carminomycin (Group 2: n = 8)
Number of subjects: 39
Study 1697822 — intervention group
Group type: EXPERIMENTAL
Intervention: BACOP (Group 3: n = 14)
Number of subjects: 39
Study 220733 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin (40 mg/m2) given every 4 weeks
Number of subjects: 65
Study 220733 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin combined with 5‐Fluorouracil, Vincristine and Prednisolone
Number of subjects: 65
Study 220733 — intervention group
Group type: COMPARATOR
Intervention: Historical group (38 patients)
Number of subjects: 65
Study 220733 — intervention group
Group type: COMPARATOR
Intervention: No treatment group (15 patients)
Number of subjects: 65
Study 220733 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin and Prednisolone (both regimens)
Number of subjects: 65
Study 31675184 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurodynamic mobilization of the median, radial, and ulnar nerves
Number of subjects: 72
Study 31675184 — intervention group
Group type: COMPARATOR
Intervention: Robotic-assisted passive movement treatment
Number of subjects: 72
Study 31684960 — intervention group
Group type: EXPERIMENTAL
Intervention: Random selection method using aerial imagery; 202 grids selected from 10 neighbourhoods for interviews.
Number of subjects: 202
Study 31684960 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed method for household sampling.
Number of subjects: 202
Study 28556578 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilberry diet (BB; n=15)
Number of subjects: 47
Study 28556578 — intervention group
Group type: EXPERIMENTAL
Intervention: Strawberry, raspberry, and cloudberry diet (SRC; n=20)
Number of subjects: 47
Study 28556578 — intervention group
Group type: COMPARATOR
Intervention: Control diet (n=12)
Number of subjects: 47
Study 25439086 — intervention group
Group type: EXPERIMENTAL
Intervention: Early systematic physical rehabilitation
Number of subjects: 63
Study 25439086 — intervention group
Group type: COMPARATOR
Intervention: No physical rehabilitation (Control)
Number of subjects: 63
Study 23486935 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive intervention (coach-focused workshop with additional supervisions)
Number of subjects: 31
Study 23486935 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular intervention (coach-focused workshop without additional supervisions)
Number of subjects: 31
Study 23486935 — intervention group
Group type: COMPARATOR
Intervention: Control (unsupervised website)
Number of subjects: 31
Study 23486935 — intervention group
Group type: EXPERIMENTAL
Intervention: High adherence to the 11+ programme
Number of subjects: 31
Study 22042958 — intervention group
Group type: EXPERIMENTAL
Intervention: paclitaxel plus sequential trastuzumab weekly for 52 weeks (arm B)
Number of subjects: 4087
Study 22042958 — intervention group
Group type: EXPERIMENTAL
Intervention: paclitaxel plus concurrent trastuzumab for 12 weeks followed by trastuzumab for 40 weeks (arm C)
Number of subjects: 4087
Study 22042958 — intervention group
Group type: COMPARATOR
Intervention: doxorubicin and cyclophosphamide every 3 weeks for four cycles followed by paclitaxel weekly for 12 weeks (arm A)
Number of subjects: 4087
Study 19589307 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia education tool
Number of subjects: 31
Study 17005077 — intervention group
Group type: EXPERIMENTAL
Intervention: Nourishing yin and Unblocking meridians Recipe (NUR) combined with opioid analgesics
Number of subjects: 84
Study 17005077 — intervention group
Group type: COMPARATOR
Intervention: Opioid analgesics alone
Number of subjects: 84
Study 15161788 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg
Number of subjects: 217
Study 15161788 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 217
Study 11549098 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe (daily doses ranging from 0.25 to 10 mg for 12 weeks)
Number of subjects: 409
Study 11549098 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 409
Study 9664584 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral infarction patients
Number of subjects: 6
Study 9664584 — intervention group
Group type: COMPARATOR
Intervention: Intracerebral hemorrhage patients
Number of subjects: 6
Study 8112928 — intervention group
Group type: EXPERIMENTAL
Intervention: neutral hypnosis
Number of subjects: 20
Study 8112928 — intervention group
Group type: EXPERIMENTAL
Intervention: deep relaxation
Number of subjects: 20
Study 8112928 — intervention group
Group type: EXPERIMENTAL
Intervention: pleasant dissociated 'out of body' imagery
Number of subjects: 20
Study 8112928 — intervention group
Group type: EXPERIMENTAL
Intervention: focused analgesia of the hand
Number of subjects: 20
Study 8112928 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 3418289 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education
Number of subjects: 3860
Study 3418289 — intervention group
Group type: EXPERIMENTAL
Intervention: Doctor's letter only
Number of subjects: 3860
Study 3418289 — intervention group
Group type: COMPARATOR
Intervention: General practitioner consultation rates
Number of subjects: 3860
Study 31628524 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin plus first-line chemotherapy (paclitaxel plus carboplatin)
Number of subjects: 44
Study 31628524 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (paclitaxel plus carboplatin)
Number of subjects: 44
Study 29162120 — intervention group
Group type: EXPERIMENTAL
Intervention: deltamethrin + PBO LLIN
Number of subjects: 16
Study 29162120 — intervention group
Group type: COMPARATOR
Intervention: deltamethrin LLIN
Number of subjects: 16
Study 29162120 — intervention group
Group type: EXPERIMENTAL
Intervention: deltamethrin + PBO LLIN (rainy/high transmission season)
Number of subjects: 16
Study 29162120 — intervention group
Group type: COMPARATOR
Intervention: deltamethrin LLIN (rainy/high transmission season)
Number of subjects: 16
Study 25240692 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA-enriched high oleic canola oil (CanolaDHA)
Number of subjects: 114
Study 25240692 — intervention group
Group type: COMPARATOR
Intervention: Conventional canola oil (Canola)
Number of subjects: 114
Study 23269119 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (6-min treadmill exercise)
Number of subjects: 42
Study 23269119 — intervention group
Group type: COMPARATOR
Intervention: Healthy nonasthmatic nonatopic term children
Number of subjects: 42
Study 22011016 — intervention group
Group type: EXPERIMENTAL
Intervention: Real rTMS (high-frequency over left dorsolateral prefrontal cortex for 25 minutes) plus individualized speech therapy
Number of subjects: 3
Study 22011016 — intervention group
Group type: COMPARATOR
Intervention: Placebo rTMS plus individualized speech therapy
Number of subjects: 3
Study 18611959 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 days of oral amoxycillin
Number of subjects: 2009
Study 18611959 — intervention group
Group type: COMPARATOR
Intervention: 5 days of co-trimoxazole
Number of subjects: 2009
Study 16481188 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapleural intercostal nerve block (IINB) with 20 ml (7.5 mg/ml) ropivacain injection at the dose of 4 ml for each space from the 4th to the 8th space.
Number of subjects: 120
Study 16481188 — intervention group
Group type: COMPARATOR
Intervention: Non-IINB (control group).
Number of subjects: 120
Study 16481188 — intervention group
Group type: EXPERIMENTAL
Intervention: IINB group mortality and morbidity.
Number of subjects: 120
Study 16481188 — intervention group
Group type: COMPARATOR
Intervention: Non-IINB group mortality and morbidity.
Number of subjects: 120